MJFF Awards Grant to Cantabio to Develop Tau-focused Therapy

MJFF Awards Grant to Cantabio to Develop Tau-focused Therapy

315564

MJFF Awards Grant to Cantabio to Develop Tau-focused Therapy

Cantabio Pharmaceuticals has been awarded a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to develop a small molecule that can reduce the aggregation of a protein called tau. The research may have applications in treating Parkinson’s and other brain diseases. “We are proud to support Cantabio’s approach targeting this pathology and building potential to slow or prevent progression for millions of people,” Marco Baptista, PhD, vice president of research programs at…

You must be logged in to read/download the full post.